165 related articles for article (PubMed ID: 15051893)
1. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
Yang S; Yang Y; Raycraft J; Zhang H; Kanan S; Guo Y; Ronai Z; Hellstrom I; Hellstrom KE
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4990-5. PubMed ID: 15051893
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE
Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939
[TBL] [Abstract][Full Text] [Related]
6. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells.
Lüthje K; Cramer SO; Ehrlich S; Veit A; Steeg C; Fleischer B; Bonin Av; Breloer M
Eur J Immunol; 2006 Aug; 36(8):2035-45. PubMed ID: 16841299
[TBL] [Abstract][Full Text] [Related]
7. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: CD83 regulates the development of cellular immunity.
Scholler N; Hayden-Ledbetter M; Dahlin A; Hellström I; Hellström KE; Ledbetter JA
J Immunol; 2002 Mar; 168(6):2599-602. PubMed ID: 11884422
[TBL] [Abstract][Full Text] [Related]
9. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
11. CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].
Scholler N; Hayden-Ledbetter M; Hellström KE; Hellström I; Ledbetter JA
J Immunol; 2001 Mar; 166(6):3865-72. PubMed ID: 11238630
[TBL] [Abstract][Full Text] [Related]
12. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
Seldon TA; Pryor R; Palkova A; Jones ML; Verma ND; Findova M; Braet K; Sheng Y; Fan Y; Zhou EY; Marks JD; Munro T; Mahler SM; Barnard RT; Fromm PD; Silveira PA; Elgundi Z; Ju X; Clark GJ; Bradstock KF; Munster DJ; Hart DN
Leukemia; 2016 Mar; 30(3):692-700. PubMed ID: 26286117
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.
Liu P; Jaffar J; Zhou Y; Yang Y; Hellström I; Hellström KE
J Immunother; 2009 Apr; 32(3):232-9. PubMed ID: 19242377
[TBL] [Abstract][Full Text] [Related]
15. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
Sun Y; Blink SE; Chen JH; Fu YX
J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
18. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
19. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.
Myers L; Lee SW; Rossi RJ; Lefrancois L; Kwon BS; Mittler RS; Croft M; Vella AT
Int Immunol; 2006 Feb; 18(2):325-33. PubMed ID: 16373363
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
